Paper Details

  1. Home
  2. Paper Details

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Author: , AraujoCarla, ChngWee-Joo, DimopoulosMeletios A, FaconThierry, FengShibao, GaidanoGianluca, GillenwaterHeidi H, GoldschmidtHartmut, Goranova-MarinovaVesselina, HungriaVania, HájekRoman, JoshuaDouglas, KaramaneshtIevgenii, LudwigHeinz, MassziTamás, MinukLeonard, MohamedNehal, MoreauPhilippe, OffidaniMassimo, OriolAlbert, OrlowskiRobert Z, PalumboAntonio, PikaTomas, PourLudek, RimashevskayaElena, RosiñolLaura, SchwarerAnthony, SpencerAndrew, StraubJan, SuvorovAleksandr, WeiselKatja

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compares the effectiveness of carfilzomib and dexamethasone to bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Paper Details　
Original Abstract of the Article :
Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortez...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(15)00464-7

データ提供：米国国立医学図書館（NLM）

Relapsed or Refractory Multiple Myeloma: A Comparative Journey Through the Desert

The fight against multiple myeloma is a relentless journey through a vast and challenging desert, with researchers constantly seeking new and effective weapons to combat this devastating disease. This study delves into the comparative efficacy of two treatment regimens for relapsed or refractory multiple myeloma: carfilzomib with dexamethasone versus bortezomib with dexamethasone. It's like setting out on a caravan journey through the desert, carefully comparing different routes to find the most effective path towards healing.

The study reveals that carfilzomib with dexamethasone demonstrates promising activity in patients with relapsed or refractory multiple myeloma, offering a potential new weapon in the fight against this complex disease. This discovery is like finding a hidden spring in the desert, offering a potential solution to a challenging problem.

Carfilzomib and Dexamethasone: A Promising New Route in the Desert of Multiple Myeloma Treatment

This study suggests that carfilzomib with dexamethasone could offer a promising alternative treatment for relapsed or refractory multiple myeloma. It's like finding a new oasis in the desert of multiple myeloma treatment, offering a potential new solution to a challenging problem.

Multiple Myeloma: Navigating the Desert of Treatment Options

This study highlights the importance of exploring new treatment options for relapsed or refractory multiple myeloma, seeking to optimize patient outcomes and improve the fight against this debilitating disease. It's like discovering a new path through a challenging desert landscape, offering hope for a brighter future.

Dr. Camel's Conclusion

This study offers a glimpse of hope for individuals with relapsed or refractory multiple myeloma, suggesting that carfilzomib with dexamethasone could provide a promising new treatment option. It's like discovering a new oasis in the desert of multiple myeloma treatment, offering a potential new solution to a challenging problem.

Date :
  1. Date Completed 2016-05-20
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

26671818

DOI: Digital Object Identifier

10.1016/S1470-2045(15)00464-7

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.